396 related articles for article (PubMed ID: 24905862)
1. Ghrelin: from discovery to cancer cachexia therapy.
Molfino A; Formiconi A; Rossi Fanelli F; Muscaritoli M
Curr Opin Clin Nutr Metab Care; 2014 Sep; 17(5):471-6. PubMed ID: 24905862
[TBL] [Abstract][Full Text] [Related]
2. Acylated and unacylated ghrelin administration to blunt muscle wasting.
Reano S; Graziani A; Filigheddu N
Curr Opin Clin Nutr Metab Care; 2014 May; 17(3):236-40. PubMed ID: 24572833
[TBL] [Abstract][Full Text] [Related]
3. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting.
Gullett NP; Hebbar G; Ziegler TR
Am J Clin Nutr; 2010 Apr; 91(4):1143S-1147S. PubMed ID: 20164318
[TBL] [Abstract][Full Text] [Related]
4. The role of ghrelin and ghrelin analogues in wasting disease.
Kamiji MM; Inui A
Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):443-51. PubMed ID: 18542005
[TBL] [Abstract][Full Text] [Related]
5. The potential of ghrelin in the treatment of cancer cachexia.
Argilés JM; Stemmler B
Expert Opin Biol Ther; 2013 Jan; 13(1):67-76. PubMed ID: 23078025
[TBL] [Abstract][Full Text] [Related]
6. Mechanism and novel therapeutic approaches to wasting in chronic disease.
Ebner N; Springer J; Kalantar-Zadeh K; Lainscak M; Doehner W; Anker SD; von Haehling S
Maturitas; 2013 Jul; 75(3):199-206. PubMed ID: 23664695
[TBL] [Abstract][Full Text] [Related]
7. The role of beta-adrenoceptor signaling in skeletal muscle: therapeutic implications for muscle wasting disorders.
Koopman R; Ryall JG; Church JE; Lynch GS
Curr Opin Clin Nutr Metab Care; 2009 Nov; 12(6):601-6. PubMed ID: 19741516
[TBL] [Abstract][Full Text] [Related]
8. Emergence of ghrelin as a treatment for cachexia syndromes.
DeBoer MD
Nutrition; 2008 Sep; 24(9):806-14. PubMed ID: 18725076
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial plasticity in cancer-related muscle wasting: potential approaches for its management.
Vitorino R; Moreira-Gonçalves D; Ferreira R
Curr Opin Clin Nutr Metab Care; 2015 May; 18(3):226-33. PubMed ID: 25783794
[TBL] [Abstract][Full Text] [Related]
10. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.
Dalton JT; Taylor RP; Mohler ML; Steiner MS
Curr Opin Support Palliat Care; 2013 Dec; 7(4):345-51. PubMed ID: 24189892
[TBL] [Abstract][Full Text] [Related]
11. Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment.
Ali S; Chen JA; Garcia JM
Curr Opin Support Palliat Care; 2013 Dec; 7(4):368-75. PubMed ID: 24145681
[TBL] [Abstract][Full Text] [Related]
12. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
Zhou X; Wang JL; Lu J; Song Y; Kwak KS; Jiao Q; Rosenfeld R; Chen Q; Boone T; Simonet WS; Lacey DL; Goldberg AL; Han HQ
Cell; 2010 Aug; 142(4):531-43. PubMed ID: 20723755
[TBL] [Abstract][Full Text] [Related]
13. On our way to targeted therapy for cachexia in cancer?
Boddaert MS; Gerritsen WR; Pinedo HM
Curr Opin Oncol; 2006 Jul; 18(4):335-40. PubMed ID: 16721127
[TBL] [Abstract][Full Text] [Related]
14. Multimodal nutrition/anabolic therapy for wasting conditions.
Balstad TR; Kaasa S; Solheim TS
Curr Opin Clin Nutr Metab Care; 2014 May; 17(3):226-35. PubMed ID: 24572835
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist.
Esposito A; Criscitiello C; Gelao L; Pravettoni G; Locatelli M; Minchella I; Di Leo M; Liuzzi R; Milani A; Massaro M; Curigliano G
Cancer Treat Rev; 2015 Nov; 41(9):793-7. PubMed ID: 26386985
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia.
Argilés JM; Busquets S; Felipe A; López-Soriano FJ
Int J Biochem Cell Biol; 2005 May; 37(5):1084-104. PubMed ID: 15743680
[TBL] [Abstract][Full Text] [Related]
17. Treatment of cachexia with ghrelin in patients with COPD.
Nagaya N; Itoh T; Murakami S; Oya H; Uematsu M; Miyatake K; Kangawa K
Chest; 2005 Sep; 128(3):1187-93. PubMed ID: 16162705
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies.
Burckart K; Beca S; Urban RJ; Sheffield-Moore M
Curr Opin Clin Nutr Metab Care; 2010 Jul; 13(4):410-6. PubMed ID: 20473155
[TBL] [Abstract][Full Text] [Related]
19. Ghrelin and cachexia: will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes?
DeBoer MD
Mol Cell Endocrinol; 2011 Jun; 340(1):97-105. PubMed ID: 21354462
[TBL] [Abstract][Full Text] [Related]
20. Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology.
Anker MS; von Haehling S; Springer J; Banach M; Anker SD
Int J Cardiol; 2013 Jan; 162(2):73-6. PubMed ID: 23174169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
